Overview

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

Status:
RECRUITING

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

Phase:

PHASE2

Details

Lead Sponsor:

Evommune, Inc.